CIRIUM
16.1.2024 10:01:26 CET | Business Wire | Press release
Two of the top five global airports for on-time performance hailed from India this year, in Cirium’s annual On-Time Performance Review.
Rajiv Gandhi International Airport came second in the global rankings with 84.42% of flights on time, and Kempegowda International Airport hot on its heels with 84.08% of flights on time, in third place.
There was also a top place finish in the medium airports category for another APAC airport, with Osaka International Airport who managed an impressive 90.71% of flights on time. There was a second-place finish in the small airports category for Chubu Centrair International Airport (NGO) with 90.17% of flights on time, just 0.12% behind the top spot.
It should also be noted that Indigo Airlines was achieved an impressive fourth place in punctuality for the Asia Pacific Airline category with 82.12% of its flights arriving on-time. While operating nearly 680,000 flights in 2023.
An on-time flight is defined as a flight that arrives within 15 minutes of the scheduled gate arrival. For an airport, it is defined as departing within 15 minutes of its scheduled departure.
Jeremy Bowen, CEO of Cirium, said: "Cirium’s annual On-Time Performance Review is a global assessment of the punctuality of all types of carriers and airports, as evidenced by the widespread representation of operations from each corner of the globe, in this year’s review. Indian airports performed particularly well, with podium finishes in the global and large airport categories, and there was further representation for the APAC region in the other two airport categories as well. I’d like to extend my congratulations to all the featured airlines and airports in this year’s review.”
Now in its 15th year, the Cirium On-Time Performance program continues to meticulously monitor global airline operational performance. Our extensive and unbiased data, derived from over 600 real-time information sources, is essential for industry stakeholders. Our data encompasses airlines, airports, global distribution systems, civil aviation authorities, and more, ensuring a comprehensive and neutral perspective.
Cirium is continuing to lead the way, worldwide, in monitoring aviation on-time performance in the New Year, as the industry adjusts to post-pandemic norms. The company’s data and analytics are designed to provide industry stakeholders with a neutral, third-party perspective, based on the widest and deepest pool of information collected and curated from more than 600 sources of real-time flight information.
These include the airlines themselves, airports, global distribution systems, positional data, civil aviation authorities, air navigation service providers, proprietary data partnerships and the internet. Cirium’s on-time performance data is backed by a completely independent board of advisors, comprised of industry experts with an unbiased view of the aviation sector. The board’s oversight ensures accuracy and proper representation of all the information the company presents.
The top performing global airports of 2023 were:
Airport |
On time ranking |
On time departure |
Total flights |
Minneapolis-St. Paul International Airport (MSP) |
1 |
84.44% |
289,817 |
Rajiv Gandhi International Airport (HYD) |
2 |
84.42% |
168,426 |
Kempegowda International Airport (BLR) |
3 |
84.08% |
237,461 |
El Dorado International Airport (BOG) |
4 |
84.01% |
292,486 |
Salt Lake City International Airport (SLC) |
5 |
83.99% |
226,705 |
The top Asia Pacific Airlines of 2023 were:
Airline |
On time ranking |
On time arrival |
Total flights |
All Nippon Airways (NH) |
1 |
82.75% |
302,279 |
Japan Airlines (JL) |
2 |
82.58% |
308,302 |
Thai AirAsia (FD) |
3 |
82.52% |
113,871 |
IndiGo (6E) |
4 |
82.12% |
678,446 |
Air New Zealand (NZ) |
5 |
79.68% |
175,876 |
The full 2023 On-Time Performance Review is available for download at Cirium.com/on-time-performance
About Cirium
Cirium is the world’s most trusted source of aviation analytics. Through powerful data and analytics, coupled with decades of industry experience, Cirium is enabling airlines, airports, travel companies, aircraft manufacturers, and financial institutions, amongst others, to make intelligent and informed decisions that improve operations, grow revenues, and enhance customer experiences.
Cirium is part of RELX, a global provider of information-based analytics and decision tools for professional and business customers. The shares of RELX PLC are traded on the London, Amsterdam and New York Stock Exchanges using the following ticker symbols: London: REL; Amsterdam: REN; New York: RELX.
For further information please follow Cirium updates on LinkedIn or visit www.cirium.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240116289335/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Rigaku and Tohoku University Establish a New Research Institute for X-Ray Metrology28.8.2026 16:00:00 CEST | Press release
Rigaku Corporation, a group company of Rigaku Holdings and a global solutions partner for X-ray analytical systems (Head Office: Akishima, Tokyo; President and CEO: Jun Kawakami; “Rigaku”), and Tohoku University (Sendai, Miyagi; President: Teiji Tominaga; “Tohoku University”) have established the Rigaku-Tohoku University Co-Creation Research Institute for X-ray Metrology: Beyond The Limits (the “Institute”) at Tohoku University on August 1, 2026. The Institute will advance X-ray metrology technology, develop new metrology methods, and foster the next generation of researchers through an initial three-year collaboration, with the possibility of extension based on its achievements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828688510/en/ Inside the Institute As semiconductors become smaller, more multilayered, and incorporate a wider range of materials, manufacturing processes are becoming increasingly complex. X-ray me
BLK: Portfolio Company of Enry’s Island S.p.A., Lists on Euronext Dublin28.8.2026 15:34:00 CEST | Press release
Enry’s Island S.p.A. (WBAG:EIOS), an international venture builder with headquarters in the Tremiti Islands and the Metaverse, announces that BLK Global PLC, one of the portfolio companies within its ecosystem, has successfully completed its admission to trading on Euronext Access Dublin. Trading in the company’s shares commenced on Friday, July 31, 2026, under ticker BLKX and ISIN GB00BPSKS130. BLK was one of the thousands of applications received by Enry’s Island which, following an assessment process based on the Enry’s Model, was selected for a one-year incubation and acceleration programme. The programme supported the company through its subsequent growth stages, ultimately leading to its current stock market listing. Alessandro Pacciana, Investor Relations Manager of Enry’s Island S.p.A., said: “BLK’s listing is the second stock market listing in two years among Enry’s Island’s portfolio companies, while Enry’s Island itself is the world’s first listed venture builder. We are pro
Zambon Announces European Commission Approval of Hopledo® for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations28.8.2026 11:00:00 CEST | Press release
Hopledo® is a first-in-class, oral, modified-release formulation of levodopa/carbidopa (LD/CD) approved for the treatment of motor fluctuations of Parkinson’s disease Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026 The approval is based on data from the Phase 3 RISE-PD trial where Hopledo® demonstrated a significant increase in Good ON time compared with immediate-release LD/CD with fewer daily doses and a comparable safety profile Zambon today announced that the European Commission (EC) has granted marketing authorization for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens. Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026. The company is working closely
MTG-I2 Safely in Orbit, Unlocking Faster and Sharper Weather Monitoring Across Europe28.8.2026 10:16:00 CEST | Press release
The Meteosat Third Generation Imager 2 satellite (MTG-I2) has successfully passed its first critical post-launch milestones, completing the first full Meteosat Third Generation constellation in orbit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828243790/en/ Credit: Arianespace livestream The imager satellite MTG-I2 is safely in orbit and operating as expected following its successful launch yesterday at 22:11 CEST on board an Ariane 6 rocket from Europe’s Spaceport in French Guiana. Our teams have established communication with the spacecraft, which has also deployed its solar panels to ensure its autonomous production of energy. MTG-I2 is in perfect shape to start its Launch and Early Operations Phase that will bring it to a higher orbit, 36 000km above Earth over the following two weeks, where a longer period of calibration and validation of its instruments will begin. This summer’s extreme weather and wildfires hav
New Daiichi Sankyo Data Underscore the Effect of Bempedoic Acid in the Real-World Management of Dyslipidemia and Cardiovascular risk28.8.2026 10:00:00 CEST | Press release
Analyses from the multinational MILOS study show that LDL-C reductions achieved with up to one year of treatment with bempedoic acid-containing therapies translate to a 17.1% relative reduction and a 4.8% absolute reduction in predicted 10-year cardiovascular risk.1 Real-world data demonstrated clinically relevant mean LDL-C reductions of at least 24.9%, regardless of patient gender or glycaemic status, after one year of follow-up.2,3 Findings presented at ESC Congress 2026 reinforce the clinical value of bempedoic acid in routine clinical practice, and demonstrate the continued investment of Daiichi Sankyo in addressing outstanding unmet needs in cardiovascular disease (CVD). Daiichi Sankyo (TSE:4568) today announced new results from the MILOS study that demonstrate the real-world impact of bempedoic acid administered either alone or as a fixed-dose combination with ezetimibe, in the management of dyslipidaemia. Presented at the European Society of Cardiology Congress 2026 in Munich,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
